Dr. Sarah Johnson

Excited to share our latest paper on CRISPR-based therapies for rare genetic disorders has been accepted in Nature Biotechnology! This work represents three years of dedicated effort by our amazing team.

Looking for a postdoctoral researcher to join our lab! We're focusing on novel CRISPR delivery methods for treating neurodegenerative disorders. Ideal candidates should have experience in molecular biology and gene editing. Please share with qualified researchers in your network.

Just returned from the International Conference on Genetic Engineering in Boston. So many inspiring talks and great networking opportunities. Particularly excited about the advances in base editing technology!

Our lab has been awarded a $1.2M grant from the NIH to continue our work on gene therapy approaches for Duchenne Muscular Dystrophy. Grateful for this opportunity to advance our research and potentially improve the lives of patients with this devastating disease.

Honored to be invited as a keynote speaker at the upcoming Genome Engineering Summit in Zurich this September. Will be presenting our latest findings on targeted gene editing in hematopoietic stem cells. Looking forward to connecting with colleagues from around the world!

Interesting new paper from the Zhang lab on prime editing efficiency in primary human cells. This could have significant implications for our current project on correcting point mutations in patient-derived cells.